Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

ALK inhibitor

- PMLiVE

UK site a casualty as Pfizer reduces pain R&D

Will shut down Granta Park facility in Cambridge with loss of 120 jobs

- PMLiVE

Pfizer’s Xalkori approved for wider use in Europe

Labelupdate gives the lung cancer therapy a new first-line indication

- PMLiVE

Pfizer signs high-level deal with GPCR specialist Heptares

Wide-rangingdeal will involve up to 10 drug targets

Michael Parini moves from Pfizer to Vertex

Will be the USbiotech's chief legal officer

Eli Lilly HQ

FDA clears Lilly’s lung cancer drug Portrazza

First biologic drug to be approved as first-line therapy for NSCLC

- PMLiVE

Pfizer and Allergan merger faces opposition over tax

Companiesagree deal to boost Pfizer's standing as world's largest pharma company

- PMLiVE

Cellectis gets big pharma partners for CAR-T therapy

Pfizer, Servier and Cellectis in three-way deal to develop CAR-T immunotherapy

- PMLiVE

FDA deems Merck KGaA and Pfizer’s avelumab a breakthrough

Could become first-in-class treatment for Merkel cell carcinoma

- PMLiVE

AZ sets price of new lung cancer drug Tagrisso

Price tag of $150,000 per year given

- PMLiVE

Merck KGaA and Pfizer move avelumab into late-stage trials

Begin phase III studies of the monoclonal antibody in lung cancer

- PMLiVE

Allergan/Pfizer takeover talks confirmed

Talks still in early stage with no certainty of deal

- PMLiVE

Is Pfizer eyeing a merger with Allergan?

Combined company value could be $330bn

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links